Emfilermin(Emfilermin) - 药物靶点：LIF_专利_临床

概要

基本信息

药物类型

生长因子

别名

LIF、Recombinant LIF protein、rhLIF

+ [2]

靶点

LIF

作用方式

刺激剂

作用机制

LIF刺激剂(白血病抑制因子刺激剂)

治疗领域

神经系统疾病泌尿生殖系统疾病内分泌与代谢疾病+ [2]

在研适应症-

非在研适应症

肌萎缩侧索硬化植入并发症不孕+ [3]

原研机构

The Walter & Eliza Hall Institute of Medical Research

在研机构-

非在研机构

Merck Serono SACSL Innovation Pty Ltd.Merck KGaA

+ [2]

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 104598

来源: *****

关联

2

项与 Emfilermin 相关的临床试验

NCT00504608

/ Completed临床1/2期

A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure

The primary objective of the study was to provide further clinical and statistical evidence of the efficacy of r-hLIF, in comparison with placebo, administered during the luteal phase after IVF and ET for improving embryo implantation in infertile women with a history of at least 2 implantation failures following transfer of fresh embryos. The secondary objective of the study was to assess the safety profile of r-hLIF in the proposed indication.

开始日期2003-04-01

申办/合作机构

Merck KGaA

NCT00504530

/ Completed临床1/2期

A Randomised, Double-blind, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Acceptability of r-hLIF for Improving Embryo Implantation Following in Vitro Fertilisation (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure.

This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.

开始日期2001-09-01

申办/合作机构

Merck KGaA

100 项与 Emfilermin 相关的临床结果

登录后查看更多信息

100 项与 Emfilermin 相关的转化医学

登录后查看更多信息

100 项与 Emfilermin 相关的专利（医药）

登录后查看更多信息

350

项与 Emfilermin 相关的文献（医药）

2025-05-01·Placenta

The role of leukemia inhibitory factor in regulating angiogenesis-related gene expression in a mouse model of recurrent miscarriage

Article

作者: Zare, Fateme ; Allahyari, Zahra ; Lotfabadi, Narges Nikoonahad

BACKGROUNDRecurrent miscarriage is an early pregnancy complication that affects approximately 1-3 % of pregnant couples. Leukemia Inhibitory Factor (LIF) plays an important role in various biological processes, including angiogenesis and pregnancy. This study aimed to evaluate the role of LIF in regulating angiogenesis-related genes in a mouse model of recurrent miscarriage.METHODFemale CBA/J mice mated with DBA/2J males were utilized as a miscarriage model. The study population was randomly assigned to three groups, normal group, mating female CBA/J mouse with male Balb/c without injection; miscarriage model control group with PBS injection; and the miscarriage group, in which LIF was injected. Following detection of a vaginal plug, mice were dissected on days 4, 7, and 14 of pregnancy. Uterine and placental tissues were collected to assess the expression of angiogenesis-related genes, including VEGF, PDGF, ANG1, FGF, and TGF-β, using real-time PCR.RESULTData analysis revealed no significant differences in the expression of angiogenesis-related genes on days 4 and 7 of pregnancy compared with the control group. However, on day 14 of pregnancy, the expression of VEGF and TGF-β was significantly elevated in the miscarriage group receiving LIF compared to other groups (P = 0.03 and P = 0.04, respectively). The placental expression of the studied genes also exhibited a non-significant increase in the miscarriage group, with VEGF and TGF-β showing the most prominent increases, although these changes were not statistically significant. Correlation analysis between uterine and placental gene expression on day 14 revealed no significant association.CONCLUSIONLIF regulates the uterine and placental expression of angiogenesis-related genes, particularly VEGF and TGF-β. These findings highlight the role of LIF in regulating angiogenesis-related gene expression and suggest that LIF could be a potential therapeutic candidate for improving pregnancy outcomes in cases of recurrent miscarriage.

2025-04-01·Proceedings of the National Academy of Sciences

Revealing the roles of the solid–electrolyte interphase in designing stable, fast-charging, low-temperature Li-ion batteries

Article

作者: Tao, Lei ; Zhao, Kejie ; Shah, Sameep Rajubhai ; Shi, Feifei ; Zhang, Hanrui ; Hwang, Sooyeon ; Huang, Weibo ; Xiong, Hui ; Liang, Zhaohui ; Guo, Yanjun ; Min, Jungki ; Lin, Feng ; Lai, Jianwei ; Shi, Chenguang ; Xia, Dawei ; Russell, Joshua A. ; Yu, Deyang ; Madsen, Louis A. ; Yang, Xixian

Designing the solid–electrolyte interphase (SEI) is critical for stable, fast-charging, low-temperature Li-ion batteries. Fostering a “fluorinated interphase,” SEI enriched with LiF, has become a popular design strategy. Although LiF possesses low Li-ion conductivity, many studies have reported favorable battery performance with fluorinated SEIs. Such a contradiction suggests that optimizing SEI must extend beyond chemical composition design to consider spatial distributions of different chemical species. In this work, we demonstrate that the impact of a fluorinated SEI on battery performance should be evaluated on a case-by-case basis. Sufficiently passivating the anode surface without impeding Li-ion transport is key. We reveal that a fluorinated SEI containing excessive and dense LiF severely impedes Li-ion transport. In contrast, a fluorinated SEI with well-dispersed LiF (i.e., small LiF aggregates well mixed with other SEI components) is advantageous, presumably due to the enhanced Li-ion transport across heterointerfaces between LiF and other SEI components. An electrolyte, 1 M LiPF 6 in 2-methyl tetrahydrofuran (2MeTHF), yields a fluorinated SEI with dispersed LiF. This electrolyte allows anodes of graphite, μSi/graphite composite, and pure Si to all deliver a stable Coulombic efficiency of 99.9% and excellent rate capability at low temperatures. Pouch cells containing layered cathodes also demonstrate impressive cycling stability over 1,000 cycles and exceptional rate capability down to −20 °C. Through experiments and theoretical modeling, we have identified a balanced SEI-based approach that achieves stable, fast-charging, low-temperature Li-ion batteries.

2025-03-12·Journal of Agricultural and Food Chemistry

Effect of Different Ratios of α-Lactalbumin to β-Casein in Infant Formula on True Ileal Digestibility and Intestinal Morphology of Suckling Piglets

Article

作者: Tang, Mengxuan ; Wescombe, Philip ; Xiong, Xia ; Li, Rui ; Wang, Jianwu ; Wu, Yuliang ; Yan, Yalu ; Moughan, Paul J. ; Yin, Yulong ; Szeto, Ignatius Man-Yau ; Hodgkinson, Suzanne M. ; Duan, Sufang ; Liu, Hongnan

Breast milk (BM) is the optimal nutrition source for infants, providing highly digestible proteins. In contrast, the digestibility of proteins in infant formula (IF) varies, influenced by differences in proteins such as α-lactalbumin (α-La) and β-casein (β-CN). This study aimed to evaluate the true ileal digestibility (TID) of amino acids (AAs) in BM and IF with varying α-La and β-CN contents using neonatal piglets. Twenty-four 11-day-old piglets (4 groups; 6 replicates/group) received either a nitrogen-free diet, IF (high infant formula (HIF) with 1.74 g/100 α-La and 2.3 g/100 β-CN; low infant formula (LIF) with 1.07 g/100 α-La and 1.85 g/100 β-CN), or BM (1.82 g/100 α-La and 3.05 g/100 β-CN) for 7 days after 3 prefeed days. IF had higher concentrations of nitrogen, serine, threonine, and proline than BM. Glutamic acid was the most abundant AA in IF and BM, while methionine in BM and LIF or tryptophan in HIF was the least. BM showed the highest TID of AAs, with the LIF had the lowest. The HIF group's TID for AAs, especially tryptophan, was similar to BM and significantly better than LIF. These results suggest that adjusting the α-La and β-CN ratio in IF can improve AA digestibility, approaching BM levels.

100 项与 Emfilermin 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06562

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不孕	临床2期	-	The Walter & Eliza Hall Institute of Medical Research	-
不孕	临床2期	-	Merck Serono SA	-
不孕	临床2期	-	Zenyth Advisors LLC	-
女性不孕症	临床2期	瑞士	-	-
女性不孕症	临床2期	瑞士	-	-
神经肌肉疾病	临床2期	-	The Walter & Eliza Hall Institute of Medical Research	-
神经肌肉疾病	临床2期	美国	-	-
神经肌肉疾病	临床2期	-	Merck Serono SA	-
神经肌肉疾病	临床2期	-	Zenyth Advisors LLC	-
神经肌肉疾病	临床2期	澳大利亚	-	-